By continuing to use this site, you consent to our use of cookies to personalize your experience and to analyze website traffic. Learn more in our Privacy Policy.

Accept
Privacy Policy

See RELiZORB real-world results #

#
Upcoming Educational Programs
#
RELiZORB (iMMOBILIZED LIPASE) CARTRIDGE

Improve Every Feed From the Outside In

RELiZORB is designed to hydrolyze fats as enteral nutrition flows through the cartridge, so essential fatty acids are ready to absorb before they even reach your patient’s gastrointestinal (GI) tract1

RELiZORB is the only FDA-cleared enzyme product that breaks down fats in enteral nutrition1

Compatible with a broad range of enteral nutrition types, and easily connects with bolus and continuous setups to augment the benefits of tube feeding1

In-line diagram of the ENFit compatible RELIZORB cartridge for enteral tube feeding
For neonates and infants 6 months of age or younger, use up to 2 cartridges per day
For infant, pediatric, and adult patients greater than 6 months of age, use up to 6 cartridges per day

How RELiZORB works1,2

  • Mimics the function of the pancreatic digestive enzyme lipase
    • Only lipase can hydrolyze fats into fatty acids and accounts for a majority of fatty acid digestion
  • Facilitates absorption of essential fatty acids and monoglycerides prior to entering your patient’s body

Lipase is covalently bound to the small white beads inside the cartridge

When enteral nutrition enters RELiZORB, fats in their triglyceride forms, including LCTs, are hydrolyzed.

#

Fatty acids, such as omega-3 (DHA and EPA), are released in their free fatty acid and monoglyceride forms and are available to be absorbed.

The lipase-bead complex iLipase® (iMMOBILIZED lipase) is retained during use by 2 filters within the cartridge as enteral nutrition flows through.1

See RELiZORB results

I’m offering RELiZORB to all of my short bowel syndrome patients who are tube fed and meet the appropriate criteria.

— Sivan Kinberg, MD

Proven to hydrolyze available fats, including medium-chain and long-chain triglycerides (MCTs and LCTs)1,3

  • LCTs are complex and contain essential fatty acids
  • Compared to MCTs, LCTs are harder to hydrolyze but provide ~10% more calories
  • Intended to provide continuous fat hydrolysis throughout the entire feed
Photo of Kayleigh administering enteral nutrition through RELiZORB to her son Caleb

Caleb, a child who tube feeds with RELiZORB, and his mom, Kayleigh

RELiZORB’s diverse range of configurations and ease of use allow it to become a quick and integral part of each tube feed to meet the nutritional needs of your patients, such as those with short bowel syndrome (SBS) and cystic fibrosis (CF).1,4

#

Compatible with a broad range of enteral nutrition types1,*

Greater compatibility puts fat hydrolysis at your fingertips.

Ready to use with your patient's tube-feeding setup, RELiZORB offers expanded compatibility with pasteurized human milk and infant and enteral formulas, including some formulas with insoluble fiber.

Click to see a list of RELiZORB-compatible enteral nutrition and pumps.

Dive deeper into our FAQs

Close up of the RELiZORB (immobilized lipase) cartridge being setup by Dr. Kinberg

See clinical results with RELiZORB

Study results

#

DHA=docosahexaenoic acid; EPA=eicosapentaenoic acid.

* Please see the Compatibility Guide for more information.

References: 1. RELiZORB. Instructions for use. Alcresta Therapeutics, Inc; 2025. 2. Whitcomb DC, Lowe ME. Human pancreatic digestive enzymes. Dig Dis Sci. 2007;52(1):1-17. doi:10.1007/s10620-006-9589-z 3. Shah ND, Limketkai BN. The use of medium-chain triglycerides in gastrointestinal disorders. Practical Gastroenterol. 2017;41(2):20-28. 4. Freedman S, Orenstein D, Black P, et al. Increased fat absorption from enteral formula through an in-line digestive cartridge in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2017;65(1):97-101. doi:10.1097/MPG.0000000000001617

RELiZORB is indicated for use in pediatric (including neonates and infants) and adult patients to hydrolyze fats during enteral feeding.

Warnings
  • RELiZORB is for use with enteral tube feeding only.
See more
#

RELiZORB is indicated for use in pediatric (including neonates and infants) and adult patients to hydrolyze fats during enteral feeding.

Warnings
  • RELiZORB is for use with enteral tube feeding only.
  • RELiZORB should not be connected to any intravenous (IV) line, setup, or system.
  • Medications should not be administered through the RELiZORB cartridge. Do not add medications to the enteral nutrition or tubing before RELiZORB. The passage of medications through RELiZORB may adversely affect the medications or the ability of RELiZORB to hydrolyze fats.
  • Fibrosing Colonopathy - Fibrosing colonopathy is a rare, serious adverse reaction associated with high-dose use of pancreatic enzyme replacement therapy in the treatment of patients with cystic fibrosis. The underlying mechanism of fibrosing colonopathy remains unknown. Patients with fibrosing colonopathy should be closely monitored because some patients may be at risk of progressing to stricture formation. RELiZORB contains lipase enzyme that is not from a porcine source. The lipase is bound to the beads, and this lipase-bead complex (iLipase) is retained within the RELiZORB cartridge. Continue to follow your physician’s guidance and porcine pancreatic enzyme labeling regarding porcine pancreatic enzyme use when used in conjunction with RELiZORB.
Cautions and Precautions
  • Do not re-use RELiZORB. RELiZORB is a single-use product. Re-use may result in contamination of the product. If re-used, RELiZORB may not effectively hydrolyze fats.
  • Do not break, alter, or place excess pressure on any part of RELiZORB. Any compromise of the structural integrity of RELiZORB may lead to improper connection to enteral feeding supplies, leakage or risk of contamination.
  • Do not use RELiZORB after the date marked on the pouch.
  • Enteral nutrition administered through RELiZORB is for immediate consumption through an enteral feeding tube. RELiZORB should not be used to process enteral nutrition for later use. This has not been tested and may result in safety issues.
  • RELiZORB is designed for use with enteral feeding pump systems with low flow/no flow alarms and enteral syringes for manual bolus by syringe (push or gravity). A detailed listing of enteral nutrition, pumps, and enteral feeding supplies compatible with RELiZORB can be found at www.relizorbhcp.com/compatibility.
  • Patients less than 1 year old may be particularly vulnerable to unplanned interruptions of feeding.
  • Do not use blenderized formulas with RELiZORB. A detailed listing of enteral nutrition compatible with RELiZORB can be found at www.relizorbhcp.com/compatibility.
  • Powdered formulas should be mixed periodically during feedings.
  • Do not use excessive force on the plunger when using RELiZORB with bolus syringe feeding method.
  • Do not rush bolus feeds. Follow guidance from your healthcare professional on how long it should take you to complete your tube feeding. Ensure all inlet and outlet connectors on RELiZORB and enteral feeding supplies are clean and dry prior to making connections.
  • In order to ensure product performance, store RELiZORB in its pouch either refrigerated or at room temperature (2°C to 27°C; 36°F to 80°F).
  • RELiZORB is indicated for use with enteral feeding only; patients should follow physician’s guidance for pancreatic enzyme replacement therapy (PERT) use for meals and snacks. Patients and patient caregivers should follow physician’s guidance regarding the need for pancreatic enzyme replacement therapy (PERT) during enteral feeding.

Review full product information for RELiZORB in the Instructions for Use.